Equities

Zenith Drugs Ltd

ZENITHDRUG:NSI

Zenith Drugs Ltd

Actions
  • Price (INR)126.40
  • Today's Change-7.35 / -5.50%
  • Shares traded153.60k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 10:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Zenith Drugs Ltd is an India-based pharmaceutical manufacturing and trading company. The Company manufactures and trades pharmaceuticals, drugs enzymes and sanitary napkins and all classes of chemicals used for manufacture of the aforesaid and all other kinds of chemicals and their by-products intermediates, derivatives, formulations, and compounds. It offers a range of formulations in various forms, such as ORS powder, liquid orals, ointments, liquid externals, and capsules. Its liquid orals products include Iron & Folic Acid Syrup IP, Hungrykop Syrup, BIozen Multivitamin Syrup, Rexkop DX Syrup, and Zoomol Plus Syrup. Its ointment products include Clobetol GM Cream, Painfree Gel, POVIZ M Ointment, and Candizen Cream. Its liquid external section products include Poviz Solutin (Lotion), Bioscaby Lotion, Permethirn Lotion, Gamma Benzene Hexachloride 1% Lotion, and Scabikop Lotion. Its capsule section products include Pyvoxee Spas Plus Capsule, BIO-Omi Capsule, and Lopagen Capsule.

  • Revenue in INR (TTM)--
  • Net income in INR--
  • Incorporated2000
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Bafna Pharmaceuticals Ltd1.44bn2.73m1.82bn618.00665.00--33.151.270.11590.115960.96--------2,326,939.00--5.45--8.2326.6935.050.195.97--0.3419----32.1528.45-35.19--116.51--
Aarey Drugs and Pharmaceuticals Ltd4.72bn65.28m1.89bn0.0026.84--22.820.40042.512.51179.80------------2.30--5.012.993.581.381.40--0.5731-----5.572.2124.20-6.46-10.07--
Krebs Biochemicals And Industries Ltd527.29m-195.67m1.91bn191.00------3.63-9.08-9.0824.47--------2,760,691.00---17.87---27.0185.8215.68-37.11-58.62---3.08-----3.291.0920.10--16.76--
Quest Laboratories Ltd825.63m100.94m1.97bn74.0017.995.0218.512.396.696.6958.3023.99------11,157,140.00--------36.72--12.23--0.890433.560.1507--33.94--100.73------
Bal Pharma Ltd3.43bn75.67m2.01bn--26.50--11.450.58634.814.81217.63------------0.5654--1.5744.0543.042.220.5638--1.36--79.3911.518.56187.4414.315.023.71
Mangalam Drugs and Organics Ltd3.58bn31.71m2.04bn432.0064.48--11.180.57082.002.00225.39--------8,279,234.00--3.28--5.8938.7627.830.88662.59--0.9785-----0.982710.12-812.51--13.92--
Zenith Drugs Ltd-100.00bn-100.00bn2.17bn----9.57----------13.21------------------------0.8679--0.5617--24.95--64.70------
Vaishali Pharma Ltd909.37m8.32m2.35bn--469.30--175.622.590.41110.411180.14------------3.21--7.5013.1416.140.91493.59--0.3948----23.852.82-89.110.1492-17.83--
Alpa Laboratories Limited1.05bn188.80m2.38bn410.0012.54--11.262.279.019.0149.93--------2,554,954.00--7.14--8.8135.1834.0818.0210.56--18.56----16.986.8733.3375.3649.57--
Data as of Sep 20 2024. Currency figures normalised to Zenith Drugs Ltd's reporting currency: Indian Rupee INR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.